Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts

Tyra Biosciences is downgraded to "Hold" ahead of key phase 2 SURF302 data for dabogratinib in FGFR3-altered IR-NMIBC patients. Multiple phase 2 readouts, including SURF302, SURF303, and BEACH301, create significant near-term binary risk and opportunity for the company. Company's SNAP platform enables selective FGFR3 targeting, aiming to address efficacy and tolerability gaps left by pan-FGFR inhibitors. With $353.9M in cash and a burn rate funding operations into 2H 2028, company is financially positioned for upcoming catalysts but faces pivotal clinical risks.